Xynomic Pharmaceuticals, Inc.
11
3
6
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
9.1%
1 terminated/withdrawn out of 11 trials
75.0%
-11.5% vs industry average
9%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Role: collaborator
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
Role: collaborator
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Role: lead
XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation
Role: lead
A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Role: lead
A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
Role: lead
Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma
Role: lead
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Role: lead
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Role: collaborator
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
Role: collaborator
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
Role: collaborator
All 11 trials loaded